Diuse large B-cell lymphomas (DLBL) constitute an heterogeneous clinico-pathological entity. To characterize molecular events related to histological subtypes, clinical presentation or outcome, we compared the mRNAs expressed in a limited series of DLBL by Dierential display-reverse transcription (DDRT) and cloned a dierential cDNA, that we called LB1. LB1 open reading frame encodes a 683 amino-acid polypeptide that does not show signi®cant homology upon comparison to protein databases, nor any structural domain relating LB1 to an already known protein family. Immuno¯uorescence analysis of transfected COS cells showed a cytoplasmic ®lamentous staining, indicating that LB1 protein is tightly associated with cytoskeletal ®bers. Two LB1 transcripts, a major 3.6 ± 3.9 Kb and a minor 2.2 Kb transcripts, were detected among human haematopoietic and non-haematopoietic lines and tissues. LB1 transcripts were abundant in testis, thymus and in tumour derived cell lines, while barely detectable in liver, prostate and kidney. Concerning DLBL, LB1 expression was high in two cases of DLBL, and low or undetectable in four others, con®rming the dierential expression previously observed in the DDRT experiment. Furthermore, LB1 gene mapped to chromosome 13q14, a region that has been involved as a chromosomal breakpoint in DLBL. The cellular function of LB1 and its relationship with B cell maturation and/or oncogenesis remain to be established.
Introduction
Diuse large B cell lymphomas (DLBL) represent 30 ± 40% of adult non-Hodgkin's Lymphomas (NHL) (Harris et al., 1994) . These lymphomas presumably represent the neoplastic transformation of proliferating peripheral B lymphocytes, and are frequently associated with chromosomal alterations of the LAZ3/Bc16 gene located on chromosome 3 at band 3q27 (Kerckaert et al., 1993; Ye et al., 1993) . This gene encodes a zinc ®nger nuclear protein containing a BTB/POZ domain , which is essential for differentiation of germinal center B cells (Dent et al., 1997; Fukuda et al., 1997) , and has been shown to function as a transcriptional repressor (Chang et al., 1996; Deweindt et al., 1995) . Rearrangements of LAZ3/Bcl6 gene and/or breakpoints at 3q27 are observed in 30 ± 40% DLBL (Bastard et al., 1994; Lo Coco et al., 1994) and more limited alterations in the 5' non-coding region of LAZ3/Bcl6, such as small deletions or punctual mutations, are seen in up to 70% of DLBL (Bernardin et al., 1997; Migliazza et al., 1995) . Beside these frequent genomic alterations, translocations t(14;18) involving Bcl2 are observed in 20% of DLBL (Jacobson et al., 1993) , mutations of p53 gene are detected in 30% of cases (Kocialkowski et al., 1995; Villuendas et al., 1993) and c-myc gene has been reported to be rearranged and/ or mutated in a small percentage of DLBL (Ladanyi et al., 1991) . The up-dated Kiel classi®cation of DLBL as centroblastic, immunoblastic or anaplastic (Stansfeld et al., 1988) proves routinely dicult and poorly reproducible (Harris et al., 1994) , although potentially clinically relevant (Engelhard et al., 1997) . Beside this morphological heterogeneity, the expression of proteins involved in apoptosis, like Bcl2 (Hermine et al., 1996) , of proteins involved in the interaction of cells with the extra-cellular matrix, like CD44 (Stauder et al., 1995) and various chromosomal abnormalities Schouten et al., 1990) have been reported to be associated with prognosis. These data suggest that variations in presentation and clinical outcome might be related to speci®c molecular events, and that the molecular characterization of DLBL should help to de®ne more homogeneous groups of patients and optimal treatment schemes.
In order to identify genes whose expression would be related to histological subtypes, clinical presentation or outcome, we compared the mRNAs expressed in a series of DLBL patients by dierential display-reverse transcription. We report here the identi®cation, cloning and characterization of LB1, a gene dierentially expressed among DLBL and encoding a cytoskeletal associated protein.
Results

Identi®cation of LB1 through dierential screening of lymphomas mRNAs
We compared the mRNAs expressed in diuse large Bcell lymphomas originating from four dierent patients by dierential display-reverse transcription (DDRT). Total RNAs extracted from DLBL frozen tissue samples were treated with DNAse I and run on a 0.8% agarose gel to check the quality of the RNAs used in the DDRT experiment (Figure 1a) . Using the T12GC anchor primer and OPA16 arbitrary decamer, a 210 bp band called LB1 was speci®cally ampli®ed only in two samples, as shown in Figure 1b . This band was absent in the control PCR reactions performed without the reverse transcription step (data not shown). This 210 bp fragment was eluted, re-ampli®ed and subjected to direct sequencing. The comparison of LB1 sequence to sequence databases allowed us to identify overlapping EST (Expressed Sequence Tag), and to generate by RT ± PCR a 520 bp cDNA fragment. Using this fragment as a probe, we detected LB1 mRNA expression in Jurkat T cell line, and thus screened a Jurkat cDNA library. Of the four positive clones isolated, three exhibited the same restriction enzyme pattern, and complete identity upon partial sequencing. The fourth clone was divergent in its 3' region, and proved to be a partially unspliced RNA, since it contained genomic sequences that did not hybridize with any transcript upon Northern blot analysis (data not shown). The longest cDNA clone isolated (3361 nt) was entirely sequenced on both strands.
Structural features of LB1 cDNA and protein
LB1
cDNA contains an open reading frame (ORF), encoding a 683 amino acids polypeptide, with the ®rst ATG (nt 91) lying in a favourable context for initiation of translation (acgATGA) (Kozak, 1996) , and preceeded by an in frame stop codon 57 nucleotides upstream (Figure 2 ). The 3'UTR exhibits two consensus AATAAA polyadenylation signal sequences (nt 2147 ± 2152 and 3182 ± 3187) (Proudfoot, 1991) and a AU-rich mRNA destabilizing motif (TATTTATT, nt 3268 ± 3275) (Zubiaga et al., 1995) (Figure 2 ). The protein encoded by the ORF exhibits a domain rich in leucines and isoleucines (aa 431 ± 506), and numerous potential protein kinase C and casein kinase II phosphorylation sites (data not shown) but LB1 protein does not display any signi®cant homology with known proteins, nor any structural domain relating it to an already known protein family.
Northern blot analysis of LB1 expression in established cell lines, lymphomas and normal tissues As LB1 cDNA was identi®ed upon DDRT screening for dierential RNAs in lymphomas, we ®rst studied LB1 expression by Northern blot analysis in a limited series of patients with DLBL and in several human cell lines, mostly derived from the B lymphocyte lineage. As shown in Figure 3a , hybridization with a LB1 cDNA probe (nt 820 ± 1263), revealed a strong expression of LB1 mRNAs, comprising a major 3.6 ± 3.9 Kb transcript and a minor 2.2 Kb transcript, in B cell lines (RS 4;11, Nalm 16, 697, Nalm 6, Ramos, Raji, RL), T cell lines (Jurkat, SUDHL1), erythroleukaemic lines (HEL, K562) as well as in non-haematopoietic lines (Hela, HepG2). LB1 appeared highly expressed in the two lymphomas (MR and VL, Figure 3b ) that displayed the LB1 cDNA band upon DDRT analysis, whereas its expression was low or undetectable in the four other DLBL tested (BS, BL, DL, TM, Figure 3b) . LB1 expression was then studied in several normal human tissues ( Figure 3c ). Although LB1 transcripts were detected in all the tissues tested, its expression level was particularly high in testis and thymus, and weak in liver, prostate and kidney. Beside these dierences in the level of expression, the ratio between the 3.6 ± 3.9 Kb and the 2.2 Kb transcripts varied widely, the shorter transcript representing less than 15% in most cell lines and tissues, but more than 40% of the transcripts in peripheral blood leukocytes as well as in the RL follicular lymphoma derived B cell line. LB1 probe also hybridized with a band larger than the major 3.6 ± 3.9 Kb transcript in the lane loaded with peripheral blood leukocytes poly (A) + RNA.
In vitro transcription-translation of LB1 cDNA
To determine if LB1 cDNA encodes a protein, a cDNA fragment containing LB1 complete ORF was subcloned in pcDNA 3.1 expression vector. In vitro transcriptiontranslation of this plasmid showed that LB1 ORF encodes a major protein product (Figure 4 , lane 1). This product migrates on SDS ± PAGE as a 85 kDa polypeptide, which is slightly higher than the 77 kDa molecular mass predicted from LB1 amino-acid composition.
Subcellular localization of LB1 protein
To investigate LB1 subcellular localization, COS cells were transiently transfected with an expression vector containing LB1 complete ORF fused in frame with six myc epitopes (LB1-pCS3-MT). Immuno¯uorescence analysis with the anti-myc antibody showed a strong cytoplasmic staining in transfected cells, that displayed a ®lamentous pattern (Figure 5a ). This staining was absent upon omission of the anti-myc antibody and in control COS cells treated with lipofectamine alone (data not shown). COS cells transfected with the empty vector (pCS3+MT) displayed mostly a nuclear granular staining, clearly dierent from that observed upon transfection of LB1-pCS3+MT (Figure 5b ). These results probably re¯ect the fact that LB1 protein, which does not present any structural feature of cytoskeletal protein by itself, tightly associates with cytoskeletal ®bers.
Chromosomal mapping of LB1 gene
The location of the LB1 gene on human chromosome 13 at position q14 was demonstrated by FISH analysis, upon hybridization of normal human metaphase chromosomes with a biotin labelled LB1 probe (data not shown).
Discussion
DDRT screening for dierential mRNAs in DLBL led to the characterization of a novel gene called LB1. Northern blot analysis of LB1 expression showed that this gene gives rise to two transcripts, a major 3.6 ± 3.9 Kb transcript and a minor 2.2 Kb one. The longest cDNA fragment isolated upon screening a Jurkat cDNA library contains 3361 nucleotides, and we presume that it represents a 3' truncated form of the major 3.6 ± 3.9 Kb transcript, since (i) 5' RACE experiments and screening another cDNA library did not reveal any longer 5' LB1 sequences; (ii) this cDNA clone does not present a consensus polyadenylation signal at its 3' end. The 2.2 Kb transcript hybridized with several probes located in the coding region (nt 354 ± 699, 820 ± 1263 and 1675 ± 1974) (data not shown), suggesting that it represents a transcript containing most if not all the ORF, and polyadenylated using the consensus polyadenylation signal AATAAA located ten nucleotides downstream the ORF.
LB1 ORF comprises 683 amino acids and gives rise to a protein product migrating with a 85 kDa apparent molecular weight on SDS ± PAGE. The polypeptide encoded by LB1 does not present any signi®cant homology, nor any structural domain relating LB1 to an already known protein family. However, transfection of COS cells showed that LB1 protein is a cytoplasmic protein, tightly associated with cytoskeletal ®bers. Preliminary experiments indicate that LB1 localization is clearly dierent from that of polymerized actin (data not shown). Further studies are needed to identify the cytoskeletal components, i.e. intermediate ®laments and/or microtubules to which LB1 is associated. It is now clear that the cytoskeleton, beside its structural role, is a highly dynamic structure, involved in cellular shape, mobility and division, but also in transduction and integration of transmembrane signals (Tapon and Hall, 1997; Yamada and Geiger, 1997) , progression through the cell cycle (Assoian and Zhu, 1997) and mRNAs transport (Bassell and Singer, 1997) . Since the dynamic properties of cytoskelal ®laments appear highly regulated by the phosphorylation state of cytoskeletal associated proteins (Foisner et al., 1996; Moon and Drubin, 1995) , it is of interest that LB1 ORF contains numerous PKC and CKII phosphorylation sites. Besides, malignant transformation is characterized by disruption of cytoskeletal organization, altered adhesion-dependent responses and deregulated expression of cytoskeletal associated proteins (Ben-Ze'ev, 1997). Stathmin, for instance, an ubiquitous phosphoprotein that destabilizes microtubules, is upregulated in many malignant cell types and tumours (Belmont and Mitchison, 1996; Hailat et al., 1990) . In the present study, LB1 mRNAs were detected in all normal tissues and established cell lines, but their expression level showed high variations in normal tissues while it was high and roughly identical in all the cell lines tested, even those established from tissues expressing very low levels of LB1 mRNAs (compare the liver and HepG2). This result suggests that LB1 mRNA level might be upregulated upon malignant transformation and/or cell line establishment.
In lymphoid tissues, LB1 appeared highly expressed in thymus, and to some extent in spleen, and displayed a particular pattern of expression in peripheral blood leukocytes (PBL), with a relatively high level of the 2.2 Kb transcript, and the presence of a larger transcript that was not observed in other tissue samples. As PBL contain cells from both the granulocyte and the lymphocyte lineage, the cellular origin of this larger transcript remains unknown. The dierential expression of LB1 in B-cell lymphomas that was detected in the DDRT experiment was further assessed by Northern Blot analysis. We investigated six patients, for whom sucient tissue sample was available. In this limited series of lymphomas, LB1 was highly expressed in two patients, one presenting with an immunoblastic, and the other with a multilobated centroblastic subtype of DLBL. By contrast, LB1 expression was low or undetectable in four patients who had a polymorphic centroblastic DLBL. These data suggest that LB1 expression might be related to morphologic characteristics of lymphomatous cells, which could re¯ect the B lymphocyte dierentiation stage aected by the neoplastic process, or other illde®ned cellular processes associated with these particular morphologic aspects. Interestingly, the LB1 gene was mapped to chromosome 13 at band q14, a region that is rearranged by translocations or interstitial deletions in about 10% DLBL (Juneja et al., 1990; Whang-Peng et al., 1995 and Chritian Bastard, personal communication) . As LB1 is highly expressed in some lymphoid tissues and deregulated in DLBL, it is tempting to speculate that it might be involved in the reorganization of the cytoskeleton associated with lymphocyte polarization, mobility, or signalling pathways initiated by the activation of adhesion, cytokine or antigen receptors (Gomez et al., 1997; Juglo and Jongstra-Bilen, 1997; Lub et al., 1997; Manie et al., 1997) .
In conclusion, we identi®ed and cloned a novel gene, encoding a cytoskeletal associated protein, which is dierentially expressed among DLBL lymphomas. Further studies are needed to identify the cytoskeletal components associated with LB1, and to determine the pattern of LB1 protein expression in normal lymphoid tissues, as well as in large series of lymphomas. Furthermore, functional studies will be essential to establish LB1 normal cellular function, and the physiological signi®cance of LB1 deregulated expression in B cell oncogenesis.
Material and methods
Material
Lymphoma tissue samples were analysed from patients with a diagnosis of DLBL, and for whom frozen tissue were available in the Department of Pathology of HoÃ pital Henri Mondor, CreÂ teil. Lymphomas were classi®ed according to the Kiel (Stansfeld et al., 1988) as well as to the REAL classi®cation (Harris et al., 1994) by applying conventional histological and immunohistochemical criteria. Amongst the six DLBL cases studied, four were subclassi®ed as polymorphic centroblastic, one as immunoblastic and one as multilobated centroblastic. To avoid variations due to cellular heterogeneity, we selected lymphomas samples that contained more than 90% tumoural B cells in the frozen tissues used to extract RNA.
.
DDRT ± PCR
Dierential display of mRNA was performed essentially as described (Liang and Pardee, 1992) . Total RNAs were extracted from frozen tissue sections using the TRIZOL reagent (GibcoBRL, Life Technology) and then treated with DNAse I (0.2 units/mg RNA, Ambion) for 10 min at 378C, extracted with phenol/chlorophorm, precipitated in 2 M LiCl overnight at 48C, and dissolved in DEPC-treated water. 1 mg of each RNA was reverse transcribed with 200 units Superscript II reverse transcriptase in the presence of 50 picomoles T12MN primers where M represents A, C or G and N is T, A, C, or G in 20 ml RT buer (25 mM Tris pH 8.3, 37.5 mM KCl, 1.5 mM MgCl 2 , 10 mM DTT, 20 mM dNTP). After heat inactivation of the reverse transcriptase at 958C for 5 min, subsequent PCR ampli®cation was done using 1/10 of the cDNA with 50 picomoles of the appropriate T12MN primer in combination with 10 picomoles of arbitrary 10-mer primer. The PCR reaction was carried out with two units Taq polymerase (Perkin Elmer) and 0.075 ml [a-
33 P]dATP (1000 Ci/mmoles) in 20 ml PCR buer (10 mM Tris pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 2 mM dNTP). The cycling parameters were as follows: 948C for 4 min/and then 40 cycles of denaturation (948C for 30 s), annealing (428C for 2 min), and elongation (728C for 30 s), followed by a 728C elongation step for 7 min. The ampli®ed cDNAs were separated on a 6% sequencing gel.
Dierentially displayed cDNAs were excised from the dried sequencing gel, boiled in 100 ml of H 2 O for 15 min, precipitated with ethanol and suspended in 10 ml of water. One quarter of the recovered cDNA were used for reampli®cation by PCR in a 40 ml reaction volume using the same primer set and PCR conditions as used in the mRNA display except a higher concentration of dNTP (20 mM). Reampli®ed cDNA fragments were cloned into pBSKII plasmid.
cDNA library screening
A human Jurkat cDNA library constructed in pSPORT plasmid according to the manufacturer's instructions (Gibco ± BRL), was screened with a RT ± PCR derived 520 bp LB1 cDNA fragment. Brie¯y, the cDNA fragment was labelled with a-32 P-dATP (3000 Ci/mmoles, Amersham) using a random primer labelling kit (Gibco ± BRL). Approximatively 10 6 cDNA clones were plated at a density of 5610 4 colonies/150-mm dish using Escherichia coli DH5a as host. Duplicate nitrocellulose ®lters were prehybridized for 4 h and hybridized in Church solution (140 mM NaH 2 PO 4 ; 360 mM Na 2 HPO 4 ; 1 mM EDTA; 7% SDS) at 658C overnight. Filters were washed at 658C in 0.56SSC, 0,1% SDS. Four positive clones were isolated and puri®ed by one additional round of screening.
DNA sequencing
Plasmid DNA and PCR products were Taq cycle sequenced using the Applied Biosystems PRISM ready reaction Dyedideoxy Terminator and Dye-Primer sequencing kits and samples run on an ABI 373A DNA sequencer.
Cell culture
Hematopoietic cell lines were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated foetal calf serum. HeLa cell line was maintained in Dulbecco's modi®ed Eagle's medium (DMEM) and COS cells were grown in Iscove modi®ed Dulbecco's medium (IMDM) supplemented as above. All cell lines were grown in a 378C incubator saturated with 5% CO 2 .
Northern blot analysis
Total RNAs were isolated using TRIZOL (Gibco ± BRL) according to the manufacturer's instructions. RNAs extracted from lymphomas or cell lines (10 mg) were denatured 10 min at 658C and subjected to electrophoresis in a 1% agarose gel containing 2 M formaldehyde, in 10 mM phosphate buer pH 7. After migration, RNAs were transferred on Hybond-N + membranes (Amersham) and ®xed by exposure to UV irradiation. Prehybridization and hybridization were performed in Quick Express Hyb solution (Clontech) with 32 P-labelled LB1 cDNA, GAPDH cDNA or ribosomal 18S (Ambion) probes according to the manufacturer's instructions.
In vitro transcription-translation
A 2.2 kb MluI ± SacI blunted cDNA fragment containing LB1 complete ORF was subcloned into pcDNA 3.1 expression vector (In Vitrogen). 1 mg of LB1-pcDNA 3.1 or 1 mg of a control plasmid encoding luciferase were transcribed and translated using TNT(T7) coupled reticulocyte lysate system (Promega). 4 ml of [ 35 S]methionine (10 mCi/mmole, Amersham) and 25 ml of rabbit reticulocyte lysate were used in each 50 ml reaction. Transcription-translation was performed during 90 min at 308C. Labelled translation products were separated on 8% SDS ± PAGE according to Laemmli, and dried gels processed to autoradiography.
Transient transfection assay and immuno¯uorescence analysis LB1 cDNA was subcloned into an eucaryotic expression vector pCS3+MT (gift from Dr F Moreau-Gachelin), fusing the total LB1 ORF in frame with six myc epitopes (MEQKLISEEDLNE). COS adherent cells were transfected by lipofectamine procedure (Gibco ± BRL). 3610 6 cells were seeded into 100-mm tissue culture plates in 10 ml of medium 24 h prior to transfection. 10 mg plasmid DNA (pCS3+MT or LB1-pCS3+MT) in 1.5 ml opti-MEM I reduced serum medium (Gibco ± BRL) were mixed with 1.5 ml optiMEM I medium containing 50 ml lipofectamine (2 mg/ml). After 30 min incubation at room temperature, the DNA/liposomes complexes were applied to COS culture dishes, previously rinsed twice with opti-MEM I medium. After 5 h incubation at 378C, complete medium supplemented with 20% SVF was added to the cultures. Twenty-four hours after transfection, COS cells were scraped in PBS, transferred on slides by cytocentrifugation and ®xed in acetone. The subcellular localization of c-myc-LB1 fusion protein was determined by indirect immuno¯uorescence, after incubation with an anti c-myc monoclonal antibody (clone 9E10 diluted 1/5), followed by incubation with a¯uorescein isothiocyanate-conjugated (FITC) goat anti mouse antibody.
FISH analysis
The Fish method for chromosome location was performed as previously described (Cherif et al., 1990) using the longest cDNA clone obtained upon screening Jurkat cDNA library. The LB1 3.3 Kb cDNA fragment was Bio-11-UTP labelled by random priming. The hybridization signal was revealed by avidin-conjugated¯uorescence isocyanate, the chromosomes counterstained with propidium iodide, and R-bands prepared.
